Evaluation of 10 years of parainfluenza virus, human metapneumovirus, and respiratory syncytial virus infections in lung transplant recipients
Open Access
- 1 December 2020
- journal article
- research article
- Published by Elsevier BV in American Journal of Transplantation
- Vol. 20 (12), 3529-3537
- https://doi.org/10.1111/ajt.16073
Abstract
No abstract availableThis publication has 42 references indexed in Scilit:
- Single-Centre Experience with Oral Ribavirin in Lung Transplant Recipients with Paramyxovirus InfectionsAntiviral Therapy, 2011
- Survival after Bronchiolitis Obliterans Syndrome among Bilateral Lung Transplant RecipientsAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Incidence and morbidity of human metapneumovirus and other community-acquired respiratory viruses in lung transplant recipientsTransplant Infectious Disease, 2010
- Community-Acquired Respiratory Viral Infections in Lung Transplant Recipients: A Single Season Cohort StudyTransplantation, 2009
- Efficacy of Oral Ribavirin in Lung Transplant Patients With Respiratory Syncytial Virus Lower Respiratory Tract InfectionThe Journal of Heart and Lung Transplantation, 2009
- Intravenous Ribavirin Is a Safe and Cost-effective Treatment for Respiratory Syncytial Virus Infection After Lung TransplantationThe Journal of Heart and Lung Transplantation, 2005
- Human Metapneumovirus Infection in Lung Transplant Recipients: Clinical Presentation and EpidemiologyThe Journal of Heart and Lung Transplantation, 2005
- Standardisation of spirometryEuropean Respiratory Journal, 2005
- The Predominant Mechanism by Which Ribavirin Exerts Its Antiviral Activity In Vitro against Flaviviruses and Paramyxoviruses Is Mediated by Inhibition of IMP DehydrogenaseJournal of Virology, 2005
- The Epidemiology of Parainfluenza Virus Infection in Lung Transplant RecipientsClinical Infectious Diseases, 2001